NasoVAX (intranasal flu vaccine) / Altimmune - LARVOL DELTA

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) (clinicaltrials.gov) - P2; N=48; Terminated; Sponsor: Altimmune, Inc.; N=96 ➔ 48; Trial completion date: Jun 2021 ➔ Feb 2021; Recruiting ➔ Terminated; Trial primary completion date: Jun 2021 ➔ Feb 2021; Enrollment

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) (clinicaltrials.gov) - P2; N=96; Recruiting; Sponsor: Altimmune, Inc.; Trial completion date: Feb 2021 ➔ Jun 2021; Trial primary completion date: Feb 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial. (PubMed, Vaccines (Basel)) - "Consistent with the intranasal route of administration, NasoVAX elicited antigen-specific mucosal IgA responses in the nasopharyngeal cavity with an increase of approximately 2-fold over baseline GMT at the mid- and high-doses. In summary, NasoVAX appeared safe and elicited a broad immune response, including humoral, cellular, and mucosal immunity, with no impact of baseline anti-adenovirus antibody at the most immunogenic dose."

Clinical • Journal • P2 data • Infectious Disease • Respiratory Diseases

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) (clinicaltrials.gov) - P2; N=96; Recruiting; Sponsor: Altimmune, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2020 ➔ Sep 2020; Trial primary completion date: Nov 2020 ➔ Feb 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) (clinicaltrials.gov) - P2; N=96; Not yet recruiting; Sponsor: Altimmune, Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • PCR